NUS vs LCTX Comparison

Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.